Background and Purpose: Cerebellar hypoperfusion in the contralateral hemisphere after stroke is well studied and termed crossed cerebellar diaschisis. However, studies of hypoperfusion in the ipsilateral thalamus have been few. The purpose of this study was to investigate the prevalence of hypoperfusion and
Brown-Sequard described the concept that brain lesions produced excitatory and inhibitory effects causing disruption of function in regions distant from the site of damage.3 Hypoperfusion in the cerebellum contralateral to the lesion is frequently observed. Baron et a12 first described this phenomenon and termed it "crossed cerebellar diaschisis." Remote effects on cerebral perfusion have been observed in regions other than the contralateral cerebellum.4,5 However, reports dealing with hypoperfusion in areas other than the cerebellum are rare, and the prevalence and characteristics of blood flow changes in the thalamus after stroke remain unclear.
We report on cerebral perfusion changes in the thalamus and cerebellum after stroke measured by using ["2Ijisopropyliodoamphetamine (123I-IMP) singlephoton emission computed tomography (SPECT). Additionally, we performed acetazolamide-stressed 12311 IMP SPECT to investigate vasodilator capacity' in the thalamus and cerebellum in which hypoperfusion was observed.
Subjects and Methods

Subjects
We examined 14 consecutive patients (patient group: eight men and six women; mean+SD age 76.2±7.3 years) with unilateral cerebral hemispheric ischemic lesions confirmed by magnetic resonance imaging. Profiles of the patients are shown in Table 1 . All lesions were confined to the area that receives blood from the middle or anterior cerebral artery. No vascular lesions in the thalamus or cerebellum were observed in any patient. To demonstrate the reproducibility of SPECT, five patients (reproducibility group: four men and one woman, age 72.0+11.5 years) with unilateral cerebral infarction who fulfilled the same criteria as above participated. The mean interval from onset of symptoms to the first SPECT examination was 12.2+5.54 days for the patient group and 11.2±+6.14 days for the reproducibility group. No significant difference in this interval between these two groups was demonstrated by Student's t test. Six normal subjects (normal group: five men and one woman, age 66.0+10.5 years) free of neurological deficits and cerebral lesions underwent SPECT without acetazolamide to establish the normal range of the asymmetry index (AI, defined below). There was no significant difference in age among these three groups, as determined by Student's t test. Informed consent was obtained from all patients and normal subjects. 
Reproducibility ofAsymmetry Index
To exclude the possibility that the interval from the first to the second SPECT study might produce AI changes in the patient group, we examined the reproducibility of AI. Reproducibility in the thalamus and cerebellum was evaluated as the absolute change of AI between the first and second studies in the reproducibility group. The patient group received the first SPECT study without acetazolamide followed by a second SPECT study with acetazolamide. The reproducibility group received the first SPECT study without acetazolamide followed by a second SPECT study, again without acetazolamide. The interval from the first to the second study was 12.9+4.27 days for the patient group and 9.20+ 2.99 days for the reproducibility group. There was no significant difference in this interval between these two groups by Student's t test.
Results
Case Report (Patient 12)
An 86-year-old man with right hemiparesis was admitted. Magnetic resonance imaging of his head demonstrated infarction in the left basal ganglia and mild atrophy of the right temporal lobe. Magnetic resonance angiography of the cerebral vessels demonstrated moderate atherosclerotic change in the cerebral arteries, while severe stenotic change was not observed in the basilar and posterior cerebral arteries. Eight days after the onset of right hemiparesis, the first SPECT study, without acetazolamide ( Figure 1, A and B) , was performed; AI was 15.4 in the thalamus and 18.3 in the cerebellum. The second SPECT study, with acetazolamide ( Figure 1, C and D) , was performed 21 days after onset of symptoms; AI in the thalamus decreased to 3.01 and AI in the cerebellum to 5.15.
Normal Values
Mean+SD AI in the normal group was 3.85+1.58 in the thalamus and 3.13+1.04 in the cerebellum. Reproducibility of AI was 1.90±0.98 in the thalamus and 1.50±+1.38 in the cerebellum. We judged that hypoperfusion was evident when a patient had an AI greater than the mean +2 SD of normal AI (i.e., AI greater than 7.01 in the thalamus and 5.21 in the cerebellum). We considered that acetazolamide stress was effective for improving Al when the AI decrease was greater than the mean±2 SD of the reproducibility of AI (i.e., an AI decrease of greater than 3.86 in the thalamus and 4.26 in the cerebellum).
SPECT Without Acetazolamide
Twelve of the 14 patients had AI values higher than 7.01 in the thalamus. In these patients, blood flow in the ipsilateral thalamus was less than in the thalamus contralateral to the lesion. Eleven of the 14 patients had AI values greater than 5.21 in the cerebellum, and blood flow in the cerebellum contralateral to the lesion was lower than in the ipsilateral region. These results indi- The results demonstrate a high prevalence of hypoamide infusion, ipsilateral thalamic (A) and contralateral perfusion after unilateral hemispheric cerebrovascular cerebellar (B) hypoperfusion is evident. After acetazolamide lesions in both the ipsilateral thalamus and the contrainfusion, hypoperfusion in thalamus (C) and cerebellum (D) lateral cerebellum. (Figure 2 ) and the cerebellum (Figure 3) amide stress. Shaded area shows mean ±2 SD AI in cerebelimproved significantly with acetazolamide stress, as lum ofsix normal subjects. poperfusion in the contralateral cerebellum has attracted much interest.245,7 Kuhl et a14 studied cerebral blood flow and the cerebral metabolic rate for glucose and reported that ipsilateral thalamic dysfunction was observed in five of 10 patients with ischemic stroke.
Wise et al' observed decreases of about 30-40% in cerebral blood flow and the cerebral metabolic rate for oxygen in the thalamus ipsilateral to cerebral infarction. An experimental study8 confirmed that local blood flow in the thalamus decreased on the ischemic side in rats with middle cerebral artery occlusion. Our results are consistent with these reports even though ipsilateral thalamic hypoperfusion was more frequently observed. Acetazolamide is a potent carbonic anhydrase inhibitor, exhibiting complete physiological inhibition of carbonic anhydrase in the red blood cells within 1 minute after the rapid intravenous injection of 1 g of the drug.9 Acetazolamide has been used to test cerebral vasodilatory capacity.' The intravenous injection of acetazolamide increases both cerebral and cerebellar blood flow within minutes in normal subjects.1"'0 Patients with impaired cerebrovascular hemodynamic reserve show an attenuated or abolished response to acetazolamide in the region of affected perfusion.1"'0 Our results demonstrate that 91.7% of the patients with ipsilateral thalamic hypoperfusion and 63.6% of the patients with contralateral cerebellar hypoperfusion showed improved AI after acetazolamide stress. Bogsrud et a17 reported that blood flow was increased by the effect of acetazolamide in the contralateral cerebellum with hypoperfusion and concluded that the cerebellar vasodilatory capacity was intact. Our results indicate that the vasodilatory response to acetazolamide after stroke is also well preserved in the thalamus.
Improvement of hypoperfusion with acetazolamide was highly evident in both the thalamus and the cerebellum in the present study. To our knowledge, only Matsuda et all" have reported acetazolamide effects on ipsilateral thalamic hypoperfusion, using technetium99m hexamethylpropyleneamine oxime SPECT. They reported that six of 10 patients showed hypoperfusion in the thalamus ipsilateral to the lesion. After acetazolamide infusion, all six patients with thalamic hypoperfusion showed augmented perfusion in the affected thalamus compared with the unaffected side." Our results are consistent with these results. We believe that ours is the first report of hypoperfusion and vasodilatory capacity in the thalamus and cerebellum after stroke using 1`I-IMP SPECT, which provides high-quality images to detect mild ischemic lesions. 12 Contralateral cerebellar atrophy is observed after stroke.13-'6 Similarly, ipsilateral thalamic atrophy may be clinically observed after stroke. 17 Fujie et al18 reported progressive shrinkage of the thalamus following middle cerebral artery occlusion in rats and speculated that retrograde degeneration may play an important role. Kataoka et al19 reported decreased glucose utilization in the thalamus after middle cerebral artery occlusion. They also reported synaptic terminal degeneration in the thalamus and suggested that retrograde degeneration of thalamic neurons occurs after thalamocortical pathway injury.19 The clinical importance of diaschisis is controversial. Because we did not undertake a long-term follow-up study, we cannot conclude whether disturbed vasodilatory capacity as demonstrated by acetazolamide stress is predictive of thalamic atrophy after stroke. However, thalamic hypoperfusion due to decreased metabolic demand may be a cause of thalamic atrophy after stroke.
